

Dr. Schär closes 2023 exceeding half a billion euros, global sales up 16%.

The UK confirms its place as one of the key markets in Europe.

Postal, 20 March 2024



For Dr. Schär, global leader in gluten-free and special nutrition, performance was positive in all regions, with the United Kingdom remaining one of the top markets. The South Tyrolean company, led by Hannes Berger, consolidates its leadership and continues its growth strategy, aiming for global sales of €600 million by 2024.

Dr. Schär ended the 2023 financial year on a positive note with global sales of €561 million (+16,8% compared to 2022), confirming the growth trend for both domestic and international markets, consolidating its leadership in the gluten-free market with the Schär brand. In the **United Kingdom, the company has an office in Warrington and a production plant in Glasgow (GDR Food Technology Ltd acquired in 2022).**

*“The results achieved represent yet another milestone for us. We are a company that is showing the ability to grow despite a rather uncertain international scenario. This has been made possible by a strong commitment to pursuing an international growth strategy and a focus on local production, which makes it easier to supply our products and also limits our CO₂ emissions - noted **Hannes Berger, CEO of Dr. Schär** - The completion of the acquisition of GDR, our first plant in the UK (dedicated to bakery), is a step in this direction, allowing us to be closer to our consumers, and testifies to the pivotal role played by the UK market in our business plan.”*

With **investments totalling €48 million** (10% of the previous year's sales) in 2023, Dr. Schär showed a strong commitment to strengthening and streamlining its production capacity in order

to meet growing market demand, but also to further accelerate its business by expanding into new regions such as South America and the Middle East.

Among the most significant transactions was acquiring Hero's gluten-free business in the Nordic countries. Through this acquisition Dr. Schär is also establishing itself as the leader in gluten-free nutrition in Norway, Denmark, Finland and Sweden.

Projects on the agenda for 2024 include the further modernisation of the Apolda and Dreihausen plants in Germany, the opening of a new production line in Spain (Alagón - Zaragoza) and the centralisation of all US operations in Swedesboro, New Jersey, a plant producing gluten-free and soy-free bread and rolls for the domestic, Canadian and Mexican markets.

Product differentiation and expansion into new nutritional areas also contribute to the company's growth strategy. Today, in addition to the gluten-free brand Schär, which is the company's core brand, the Dr. Schär portfolio also includes Kanso and its prescription-based, ketogenic diet products, and the low-protein Flavis line.

Press contact:

Dr. Schär AG / SPA
Winkelau 9
Burgstall / Postal
Italy

Stefania Cosimi
Telephone: +39 (0) 473 293 564
Email: Stefania.cosimi@drschaer.com

World Media Wire
Kemp House, 152 -160 City Road
London
United Kingdom

Kristin Eketoft
Telephone: +46 (0) 70 247 69 77
Email: kristin.eketoft@worldmediawire.com

About Dr. Schär:

Our story began in 1922 in South Tyrol, the heart of the Alps, with a vision to improve the lives of people with special nutritional needs. Ever since the company was founded, proximity to the consumer has been our guiding commitment. Our core competence combines the specific, complex requirements placed on nutrition with joy and pleasure of life. Responsibility, progress and proximity are the values that give us our stability and reliability. We are a family-run company with a global reach, with 18 sites in 12 countries and 1,800 employees worldwide. Our products are available in over 100 countries. www.drschaer.com